Arrowhead Pharmaceuticals (ARWR) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ARWR · Stock Price

USD 77.95+64.92 (+498.23%)

Market Cap: $10.7B

Historical price data

Market Cap: $10.7BPipeline: 52 drugs (9 Phase 3)Patents: 20Founded: 1989HQ: Pasadena, United States

Sector Ranking#6 in RNA Therapeutics (non-mRNA)#16 in Rare & Orphan Diseases

Overview

Arrowhead Pharmaceuticals is a leader in RNAi therapeutics, driven by its mission to 'Target the Gene, Silence the Disease.' The company has achieved significant validation through its proprietary TRiM™ platform, which enables extrahepatic delivery and has generated a robust clinical pipeline, including multiple Phase 3 assets in cardiometabolic disorders. Its strategy focuses on advancing wholly-owned programs in high-need areas while selectively pursuing strategic partnerships to expand its reach and resource development.

CardiovascularMetabolicRare Diseases

Technology Platform

The TRiM™ (Targeted RNAi Molecule) platform is a proprietary ligand-conjugate system enabling tissue-specific delivery of RNAi therapeutics, allowing for potent and durable gene silencing beyond the liver with simple, subcutaneously administered molecules.

Pipeline

52

52 drugs in pipeline9 in Phase 3

Drug	Indication	Stage
Plozasiran Injection + Placebo	Hypertriglyceridemia	Phase 3
Plozasiran + Placebo	Familial Chylomicronemia	Phase 3
Plozasiran + Placebo	Severe Hypertriglyceridemia	Phase 3
zodasiran Injection + Placebo	Homozygous Familial Hypercholesterolemia	Phase 3
Zodasiran	Homozygous Familial Hypercholesterolemia	Phase 3

FDA Approved Drugs

1

REDEMPLONDANov 18, 2025

Opportunities

Arrowhead's near-term opportunity lies in capturing significant market share in large cardiometabolic indications like severe hypertriglyceridemia with its potent, quarterly-dosed therapies.

Long-term, its TRiM™ platform's ability to target genes in extrahepatic tissues (lung, heart, CNS) opens vast new therapeutic areas and partnership potential.

Risk Factors

The primary risks are clinical failure in ongoing Phase 3 trials, regulatory setbacks, and intense competition in the RNAi and cardiometabolic spaces from established players like Alnylam and Ionis.

Execution risk in building a commercial organization and future capital needs also pose challenges.

Competitive Landscape

Arrowhead competes directly with Alnylam, the RNAi leader, and Ionis in antisense, particularly in cardiometabolic targets. Its key differentiator is the TRiM™ platform's validated extrahepatic delivery capability, which allows it to pursue disease targets beyond the liver where competition is less mature.